• On-going

  • Planned

Hematologic Malignancies

Asset Commercial Rights Indication Line Regimen Pre-clinical Phase 1 Phase 2 Phase 3 BLA

Felzartamab TJ202
Differentiated CD38 antibody

Greater China

MM

3L
Mono

2L
TJ202 + Lenalidomide

Potential 1L
New Combo

Lemzoparlimab TJC4
Novel CD47 antibody

Greater China (Excluding Taiwan), Global (AbbVie)

MDS

AML

NHL

1L
TJC4 + Azacitidine

1L
TJC4 + Azacitidine

2L
TJC4 + Rituximab

Potential 1L
New Combo

Solid Tumors

Asset Commercial Rights Indication Line Regimen Pre-clinical Phase 1 Phase 2 Phase 3 BLA

Lemzoparlimab TJC4
Novel CD47 antibody

Greater China (Excluding Taiwan), Global (AbbVie)

Melanoma, GC, HNC

NSCLC, OC

2L
TJC4 + Toripalimab

2L
TJC4 + Pembrolizumab

Uliledlimab TJD5
Differentiated CD73 antibody

Global

NSCLC

Solid Tumors

Solid Tumors

Potential 1L
TJD5 + Toripalimab

2L
TJD5 + Toripalimab

2L
TJD5 + Atezolizumab

Enoblituzumab TJ271
Novel B7-H3 antibody

Greater China

NSCLC

Bladder Cancer

Potential 1L
TJ271 + Pembrolizumab

1L, 2L
TJ271 + Pembrolizumab

TJ210
Novel C5aR antibody

Greater China,
S. Korea,
Global Shared

Solid Tumors

Solid Tumors

2L
TJ210 + Toripalimab

2L
Mono

Efineptakin Alfa TJ107
Novel long-acting IL-7

Greater China

Glioblastoma

TNBC, HNC

1L, 2L
TJ107 + Temozolomide

2L
TJ107 + Pembrolizumab

TJ-CD4B
Novel Claudin 18.2 x 4-1BB
bi-specific antibody

Greater China,
Global Shared

GC, PDAC

2L
Mono

TJ-L14B
Differentiated PD-L1 x 4-1BB
bi-specific antibody

Global Shared

Solid Tumors

Mono

Global

Solid Tumors

Multiple Programs:
Drug Candidates,
CMC Pre-Clinical Stage

Other Assets

Asset Commercial Rights Indication Line Regimen Pre-clinical Phase 1 Phase 2 Phase 3 BLA

Eftansomatropin Alfa TJ101
Differentiated long-acting growth hormone

China

PGHD

Mono

Plonmarlimab TJM2
GM-CSF antibody

Global

CRS

Mono

Abbreviations

  • AML = Acute Myeloid Leukemia
  • BC = Bladder Cancer
  • CRS = Cytokine Release Syndrome
  • GC = Gastric Cancer
  • HNC = Head & Neck Cancers
  • MDS = Myelodysplastic Syndromes
  • MM = Multiple Myeloma
  • NHL = Non-Hodgkin’s Lymphoma
  • NSCLC = Non-Small Cell Lung Cancer
  • OC = Ovarian Cancer
  • PDAC = Pancreatic ductal adenocarcinoma
  • PGHD = Pediatric Growth Hormone Deficiency
  • TNBC = Triple-Negative Breast Cancer

Pipeline as of June 2022